Paraoxonase: Its antiatherogenic role in chronic renal failure

Indian Journal of Nephrology

Volumn 20, Issue 1, 2010, Pages 9-14

  Prakash, M ^a   Phani, N M ^a   Kavya, R ^a   Supriya, M ^a  

^a KASTURBA MEDICAL COLLEGE   (India)

Author keywords

Atherosclerosis; Chronic renal failure; Hemodialysis; High density lipoprotein; Low density lipoprotein oxidation; Paraoxonase

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; ARYLDIALKYLPHOSPHATASE 2; ARYLDIALKYLPHOSPHATASE 3; HIGH DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHEMICAL ANALYSIS; CHRONIC KIDNEY FAILURE; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME STRUCTURE; ENZYME SUBSTRATE; HEMODIALYSIS; HUMAN; PROTEIN FUNCTION; REVIEW; SPECTROPHOTOMETER;

EID: 77953392986     PISSN: 09714065     EISSN: 19983662     Source Type: Journal    
DOI: 10.4103/0971-4065.62088     Document Type: Review

References (74)

1. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996;33:498-509. (Pubitemid 26159866)
2. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA. Paraoxonase: Biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996;7:69-76.
3. Hegele RA. Paraoxonase genes and disease. Ann Med 1999;31:217-224
4. Clendenning JB, Humbert R, Green ED, Wood C, Traver D, Furlong CE. Structural organisation of the human PON1 gene. Genomics 1996;35:586-589 (Pubitemid 26270027)
5. Getz GS, Reardon CA. Paraoxonase, a cardioprotective enzyme; continuing issues. Curr Opin Lipidol 2004;15:261-266
6. Ng CJ, Wadleigh DJ, Gangopadhyay A, Hama S, Grijalva V, Navab M, et al. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem 2001;276:44444-44449 (Pubitemid 37391215)
7. Reddy ST, Wadleigh DJ, Grijalva V, Ng C, Hama S, Gangopadhyay A, et al. Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to parao-xonase-1 protein but is not regulated by oxidized lipids. Arterioscler Thromb Vasc Biol 2001;21:542-547 (Pubitemid 32323386)
8. Mackness ML, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoproteins. FEBS Lett 1991;286:152-154
9. Mackness MI, Arrol S, Abbott C, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 1993;104:129-135 (Pubitemid 24035640)
10. Mackness ML, Durrington PN. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 1995;115:243-253
11. Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffman A, et al. Human serum paraoxonase (PON) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 2000;101:2510-2517 (Pubitemid 30366256)
12. Aviram M, Rosenblat M, Bisgaier CL, NewtonRS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. J Clin Invest 1998;101:1581-1590
13. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001;21:473-480
14. Rodrigo L, Mackness B, Durrington PN, Hernandez A, Mackness MI. Hydrolysis of platelet-activating factor by human serum paraoxonase. Biochem J 2001;354:1-7. (Pubitemid 32183437)
15. Billecke S, Draganov D, Counsell R, Stetson P, Watson C, Hsu C, La Du BN. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos 2000;28:1335-1342
16. Jakubowski H. Calcium-dependent human serum homocysteine thiolactone hydrolase. J Biol Chem 2000;275:3957-3962
17. Draganov DI, Stetson PL, Watson CE, Billecke SS, La Du BN. Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem 2000;275:33435-33442
18. Aviram M, Rosenblat M. Paraoxonases and cardiovascular diseases: Pharmacological and nutritional influences. Curr Opin Lipidol 2005;16:393-399 (Pubitemid 41017622)
19. Fuhrman B, Volkova N, Aviram M. Paraoxonase 1 (PON1) is present in postprandial Chylomicrons. Atherosclerosis 2005;180:55-61. (Pubitemid 40501352)
20. James RW, Deakin SP. The importance of high-density lipoproteins for paraoxonase1 secretion, stability and activity. Free Rad Biol Med 2004;37:1986-1994
21. Kaplan M, Aviram M. Oxidized low density lipoprotein: Atherogenic and proinflammatory characteristics during macrophage foam cell formation. An inhibitory role for nutritional antioxidants and serum paraoxonase. Clin Chem Lab Med 1999;37:777-787 (Pubitemid 29471943)
22. Betowski J, Wójcicka G, Marciniak A. Species- and substrate-specific stimulation of human plasma paraoxonase 1 (PON1) activity by high chloride concentration. Acta Biochimica Polonica 2002;49:927-936 (Pubitemid 135702944)
23. Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res 2005;46:1239-1247 (Pubitemid 43109838)
24. Schiavon R, De Fanti E, Giavarina D, Biasioli S, Cavalcanti G, Guidi G. Serum paraoxonase activity is decreased in uremic patients. Clin Chim Acta 1996;247:71-80. (Pubitemid 26101430)
25. Paragh G, Seres I, Balogh Z, Varga Z, Kárpáti I, Mátyus J, et al. The Serum Paraoxonase Activity in Patients with Chronic Renal Failure and Hyperlipidemia. Nephron 1998;80:166-170 (Pubitemid 28458792)
26. Gan KN, Smolen A, Eckerson HW, La Du BN. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos 1991;19:100-106
27. Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983;35:1126-1138
28. Hasselwander O, McMaster D, Damian G, Fogarty A, Maxwell DP, Nicholls P, et al. Serum Paraoxonase and Platelet-Activating Factor Acetylhydrolase in Chronic Renal Failure. Clinical Chemistry 1998;44:179-181 (Pubitemid 28042485)
29. Connelly PW, Maguire GF, Picardo CM, Teiber JF, Draganov D. Development of an immunoblot assay with infrared fluorescence to quantify paraoxonase 1 in serum and plasma. J Lipid Res 2008;49:245-250
30. Kujiraoka T, Oka T, Ishihara M, Egashira T, Fujioka T, Saito E, et al. A sandwich enzyme-linked immunosorbent assay for human serum paraoxonase concentration. J Lipid Res 2004;41:1358-1363
31. Soukharev S, Hammond DJ. A fluorogenic substrate for detection of organophosphatase activity. Anal Biochem 327: 140-148, 2004. (Pubitemid 38372161)
32. Simpson NE. Serum arylestarase levels of activity in twins and their parents. Am J Hum Genet 1971;23:375-382
33. Garin MC, James RW, Dussoix P, Blanch H, Passa P, Froguel P, et al. Paraoxanase polymorphism Met-Leu 54 is associated with modified serum concentrations of enzyme. A possible link between the paraoxanase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest 1997;99:62-66 (Pubitemid 27058295)
34. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993;3:73-76 (Pubitemid 23063292)
35. Himbergen TM, Roest M, Graaf JD, Jansen EH, Hattori H, Kastelein JJ, et al. Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hyperchole sterolemia. J Lipid Res 2005;46:445-451 (Pubitemid 43109780)
36. Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M, Erogul J, Hsu C, Dunlop C, La Du B. Arterioscler Thromb Vasc Biol 1998;18:1617-1624
37. Sorenson RC, Bisgaier CL, Aviram M, Hsu C, Billeckes, La Du BN. Human Serum paraoxanase/arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: Apolipoprotein A-I stabilizes aactivity. Atheroscl Thromb Vasc Biol 1999;19:2214-2225 (Pubitemid 29422255)
38. Mackness MI, Abbott CA, Arrol S, Durrington PN. The role of high density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J 1993;294:829-835 (Pubitemid 23286573)
39. Michael I, Sharon Arrol, Paul N. Durrington. Paraoxanse prevents accumulation of lipoperoxides in low-density lipoproteins. FEBS 1991;286:152-154
40. Mertens A, Holvoet P. Oxidized LDL and HDL: Antigonists in atherothrombosis. FASEB J 2001;15:2073-2084 (Pubitemid 32927925)
41. James RW, Leviev I, Righetti A. Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation 2000;101:2252-2257 (Pubitemid 30317126)
42. Nishio E, Watanabe Y. Cigarette smoke extract inhibits plasma paraoxanase activity by modification of the enzyme's free thiols. Biochem Biophysics Res Commun 1997;236:289-293 (Pubitemid 27373286)
43. Jarvik GP, Tsai NT, McKinstry LA, Wani R, Brophy VH, Richter RJ, et al. Vitamin C and E intake is associated with increased paraoxonase activity. Arterioscler Thromb Vasc Biol 2002;22:1329-1333 (Pubitemid 34875745)
44. Van Der Gaag MS, Van Tol A, Scheek LM, James RW, Urgert R, Schaafsma G, et al. Daily moderate alcohol consumption increases serum paraoxonase activity: A diet-controlled, randomised intervention study in middle-aged men. Atherosclerosis 1999;147:405-410 (Pubitemid 29512273)
45. Aviram M, Rosenblat M, Bisgaier CL, Newton RS. Atorvastatin and gemfibrozil metabolites, but not the parent drugs are potent antioxidants against lipoprotein oxidation. Atherosclerosis 1998;138:271-280 (Pubitemid 28314098)
46. Paragh G, Balogh Z, Seres I, Harangi M, Boda J, Kovacs P. Effect of gemfibrozil on HDL-associated serum paraoxonase activity and lipoprotein profile in patients with hyperlipidaemia. Clin Drug Invest 2000;19:277-282 (Pubitemid 30216001)
47. Tomas M, Senti M, Garcia-Faria F, Vila J, Torrents A, Covas M, et al. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolaemic patients. Arterioscler Thromb Vasc Biol 2000;20:2113-2119
48. Hayek T, Fuhrman B, Vaya J, Rosenblat M, Belinky P, Coleman R, et al. Reduced progression of atherosclerosis in apolipoprotein E deficient mice following consumption of red wine, or its polyphenols quercetin or catechin, is associated with reduced susceptibility of LDL to oxidation and aggregation. Arterioscler Thromb Vasc Biol 1997;17:2744-2752 (Pubitemid 28016017)
49. Collins AJ, Hanson G, Umen A, Kjellstrand C, Keshaviah P. Changing risk factor demographics in end-stage renal disease patients entering hemodialysis and impact on long-term mortality. Am J Kidney Dis 1990;15:422-432 (Pubitemid 20174012)
50. Chan MK, Varghese Z, Moorhead JF. Lipid abnormalities in uremia, dialysis, and transplantation. Kidney Int 1981;19:625-637 (Pubitemid 11064667)
51. Heuck CC, Ritz E. Hyperlipoproteinemia in renal insufficiency. Nephron 1980;25:1-7. (Pubitemid 10215854)
52. Rapoport J, Aviram M, Chaimovitz C, Brook JG. Defective high-density lipoprotein composition in patients on chronic hemodialysis. A possible mechanism for accelerated atherosclerosis. N Engl J Med 1978;299:1326-1329 (Pubitemid 9106161)
53. Staprans I, Felts JM, Zacherle B. Apoprotein composition of plasma lipoproteins in uremic patients on hemodialysis. Clin Chim Acta 1973;93:135-143
54. Goldberg AP, Sherrard DJ, Brunzell JD. Adipose tissue lipoprotein lipase in chronic hemodialysis: Role in plasma triglyceride metabolism. J Clin Endocrinol Metab 1978;47:1173-1182
55. Mordasini R, Frey F, Flury W, Klose G, Greten H. Selective deficiency of hepatic triglyceride lipase in uremic patients. N Engl J Med 1977;297:1362-1366 (Pubitemid 8256293)
56. McLeod R, Reeve CE, Frohlich J. Plasma lipoproteins and lecithin: Cholesterol acyltransferase distribution in patients on dialysis. Kidney Int 1984;25:683-688 (Pubitemid 14079964)
57. Burke JF, Francos GC, Moore LL, Cho SY, Lasker N. Accelerated atherosclerosis in chronic dialysis patients - another look. Nephron 1978;21:181-185
58. Lazarus JM, Lowrie EG, Hampers CL, Merrill JP. Cardiovascular disease in uremic patients on hemodialysis. Kidney Int 1975;2:167-175
59. Dantoine TF, Debord J, Charmes JP, Merle L, Marquet P, Lachatre G, et al. Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol 1998;9:2082-2088 (Pubitemid 28482156)
60. Gugliucci L, Mehlhaff K, Kinugasa E, Ogata H, Hermo R, Schulze J, et al. Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis. Correlation with low molecular AGE adducts clearance. Clinica Chimica 2007;377:213-220 (Pubitemid 44920216)
61. Roxborough HE, Millar CA, McEneny J, Young IS. Carbamylation inhibits the ferroxidase activity of ceruloplasmin. Biochem Biophys Res Commun 1995;214:1073-1078
62. Prakash M, Shetty JK, Rao L, Sharma S, Rodrigues A, Prabhu R. Serum paraoxonase activity and protein thiols in chronic renal failure patients. Ind J Nephrology 2008;18:13-16
63. Shetty JK, Prakash M, Tripathy S, Verma M, Shashidhar KN, Sureshbabu P. Serum Paraoxonase Activity and Protein Thiols in Chronic Renal Failure Patients. Asian J Biochem 2007;2:274-278
64. Krishnaswamy PR, Rao A, Murali W Ballal HS. Paraoxonase activity and antibodies to oxidized LDL in chronic renal failure patients on renal replacement therapy. Indian J Clin Biochem 2006;21:173-176 (Pubitemid 44756948)
65. Schiavon R, De Fanti E, Giavarina D, Biasioli S, Cavalcanti G, Guidi G. Serum paraoxonase activity is decreased in uremic patients. Clin Chim Acta 1996;247:71-80. (Pubitemid 26101430)
66. Mackness MI, Hallam SD, Peard T, Warner S, Walker CH. The separation of sheep and human serum A -esterase activity with the lipoprotein fraction by ultracentrifugation. Comp Biochem Physiol B 1985;82:675-677
67. Dirican M, Akca R, Sarandol E, Dilel K. Seum paraoxonase activity in uremic predialysis and hemodialysis patients. Nephrol 2004;17:813-818 (Pubitemid 41158301)
68. Lahrach H, Ghalim N, Taki H, Kettani A, Er-Rachdi L, Ramdani B, et al. Serum paraoxonase activity, high-sensitivity C-reactive protein, and lipoprotein disturbances in end-stage renal disease patients on long-term hemodialysis. J Clin Lipidol 2008;2:43-50. (Pubitemid 351258915)
69. Aslan M, Selek S, Koylu AO, Bolukbas C, Bolukbas FF, Celik H, et al. PON1 status in haemodialysis patients and the impact of hepatitis C. Clin Biochem 2007;40:609-614 (Pubitemid 46829066)
70. Jakubowaski H. Calcium-dependant human serum homocysteine thiolactone hydrolase: A protective mechanism against protein N-homocysteinylation. J Biol Chem 2000; 275:3957-3962.
71. Beltowaski J. Protein homocysteinylation: A new mechanism of atherogenesis ? Postepy Hig Med Dow 2005 (Online); 59:392-404.
72. Jakubowski H. Homocysteine thiolactone: Metabolic origin and protein homocysteinylation in humans. J Nutr 2000; 130:377S-381S. (Pubitemid 30073754)
73. Dronca M, Pa ca SP, Neme B, Vlase L, Vladutiu D. Serum paraoxonase 1 activities and homocysteinemia in hemodialysis patients. Clin Chem Lab Med 2008;46:880-881 (Pubitemid 351821639)
74. Janel N, Robert K, Demuth K, Gouedard C, Barouki R, Chasse JF. Inverse correlation between phenylacetate hydrolase activity of the serum PON1 protein and homocysteinemia in humans. Thromb Haemost 2005;93:182-183 (Pubitemid 40142600)